While advancements in understanding the genetic basis of cancer have fueled the rise of personalized medicine, significant experimental challenges remain.  Accurately identifying the complete spectrum of somatic mutations driving tumorigenesis in individual patients presents a considerable hurdle.  Next-generation sequencing, while powerful, faces limitations in detecting low-frequency mutations and accurately distinguishing driver mutations from passenger mutations.  Furthermore, the complex interplay between genetic alterations and epigenetic modifications, including DNA methylation and histone modification patterns, necessitates sophisticated integrated analyses that are computationally demanding and require robust bioinformatics pipelines.  The translation of genomic findings into effective therapeutic strategies is further complicated by the heterogeneity within and between tumors, with clonal evolution and the emergence of drug resistance posing significant challenges to long-term treatment success.  Finally, the ethical considerations surrounding data privacy, access to advanced genomic testing, and equitable distribution of personalized therapies require careful consideration to ensure the responsible implementation of this burgeoning field.  Addressing these experimental challenges is crucial for realizing the full potential of personalized cancer medicine.